
Errata

The July 10, 2016, article by Denduluri et al, entitled “Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline” (J Clin Oncol 34:2416-2427, 2016), contained an error.

Under Recommendations in the Bottom Line section, based on the findings of the trial conducted by the Gruppo Italiano Mammella investigators, which demonstrated improved disease-free survival and overall survival observed with four cycles of epirubicin 90 mg/m² and cyclophosphamide

600 mg/m² followed by four cycles of paclitaxel 175 mg/m² delivered every two weeks (dose-dense EC-P) compared to every 3 weeks, the guideline adaptation should have included the dose-dense EC-P regimen, as provided below, in the list of acceptable adjuvant chemotherapy regimens for patients with higher-risk early breast cancer.

Dose-dense epirubicin 90 mg/m², cyclophosphamide 600 mg/m² every 2 weeks 4 cycles → paclitaxel 175 mg/m² every 2 weeks for 4 cycles.

The online version has been corrected in departure from the print. The authors regret the omission.

DOI: 10.1200/JCO.2016.71.6175; published January 10, 2017

The October 10, 2016, article by Ganzel et al, entitled “Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008” (J Clin Oncol 34:3544-3553, 2016), contained an error.

Peter H. Wiernik was omitted as an author on this manuscript. He should have been listed as the second to last author in the byline, between Dr Cripe and Dr Tallman. The byline should have read as: Chezi Ganzel, Judith Manola, Dan Douer, Jacob M. Rowe, Hugo F. Fernandez, Elisabeth M. Paietta, Mark R. Litzow, Ju-Whei Lee, Selina M. Luger, Hillard M. Lazarus, Larry D. Cripe, **Peter H. Wiernik**, and Martin S. Tallman.

His affiliation is at the **St. Luke’s-Roosevelt Medical Center**.

His contributions are **Collection and assembly of data, manuscript writing, and final approval of manuscript**.

His conflict of interest information is provided below.

Honoraria: TRACON Pharma, Novartis

Speakers’ Bureau: Novartis

Travel, Accommodations, Expenses: Novartis

The online version has been corrected in departure from the print. The authors apologize for the error.

DOI: 10.1200/JCO.2016.71.6407; published January 10, 2017
